Compare Schlumberger NV (SLB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs State Street SPDR S&P Biotech ETF — how do they compare? Schlumberger NV trades at $52.66 (market cap $79.67B), while State Street SPDR S&P Biotech ETF trades at $159.4. The key difference: Schlumberger NV pays a 2.2% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Schlumberger NV nearer its low. Which is the better fit depends on your goals.
| SLB | XBI | |
|---|---|---|
Market Cap | $79.67B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $58.01 | $164.28 |
52-Week Low | $31.72 | $88.79 |
Enterprise Value | $88.40B | — |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB (NYSE: SLB) trades at $53.02, down 0.34% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.55 exceeding expectations. Revenue trends show stability at $35.7B in 2025, though net income margin declined to 8.53%. Analyst consensus remains overwhelmingly positive with 85% buy ratings and a $63 price target representing 19% upside potential.
SLB's outlook is supported by robust digital and production systems growth, though Middle East exposure and net debt pose near-term risks. The stock offers 2.25% dividend yield with recent quarterly payouts of $0.30. While technical indicators show some overbought conditions with RSI at 74, fundamental strength and Wall Street optimism suggest continued upside potential, balanced by geopolitical and margin compression risks.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
